8th Annual Cell Line Development and Engineering Asia 2019
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

8th Annual Cell Line Development and Engineering Asia 2019

14 – 16 May 2019, China

Book Now Download Brochure

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

IBC’s 7th Annual Cell Line Development and Engineering Asia is part of Biopharma Development and Production (BDP) Week 2018. The industry’s foremost event showcases the views of top technical professionals in both research and industry best practices in engineering and optimizing cell lines for low cost, high quality, high productivity and scalability. Benchmark R&D, regulatory and commercial considerations between China and the rest of the world, and network across multiple events to make the most of your investment.

2018 Attendees List

View list >>

Key highlights

  • 300+ Companies, 70+ speakers, 60+ Sessions
  • Unparalleled learning and targeted networking across three 3 co-located events
  • Innovative approaches in early cell line development
  • Revolution of Gene-editing tools in Cell Line Engineering
  • Optimizing Technologies for Antibody therapy
  • Scale-up and Process Development
  • Assuring High Yield and High Quality
  • Preview latest equipment and technologies and hear from top vendors on how they are partnering with your peers
  • Innovation in technologies and manufacturing process

Choose your language

Part of

Biopharma Development & Production >>

Co-Located Events

Biosimilars Asia >>
Cell Line Development and Engineering >>
Biomanufacturing >>

agenda

8:00 am

Registration Opens and Morning Coffee

9:00 am

Chairperson’s Opening Remarks

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS 2018 生物制药研发制造大会开幕全体会议

9:10 am

  • Innovation in biopharma pipelines – what developments can we expect?
  • Recent regulatory developments – obstacle or opportunity?
  • How digitalization of the BioPharma industry is creating new value propositions
  • Biomanufacturing market snapshot in China 
  • Biosimilars market potential – what can we achieve?
  • New trends in cell line development   

 

 

10:10 am

  • Investment outlook and market drivers for biopharma investments in Asia
  • Taking advantage of a variety of innovative R&D financing and partnership models
  • Assessing current investment climate and its implications on Chinese biotech market

10:50 am

Morning Networking and Refreshment Break.

END OF OPENING PLENARY AND CELL LINE DEVELOPMENT & ENGINEERING ASIA COMMENCES

11:20 am

Chairperson’s Opening Remarks

Sunny Zhou, Professor, Department of Chemistry and Chemical Biology Faculty Fellow, Barnett Institute of Chemical and Biological Analysis Northeastern University, Boston, Massachusetts

CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND STABILITY 克隆选择策略:建立可克隆性和稳定性

11:30 am

  • Novel technologies engineered to provide process control while at the same time enabling optimal leverage of the cell factory using ChemStress fingerprinting
  • Utility of CHO cell factories derives from exploitation of their acquired genetic/functional variation, which enable industry to identify cell lineages with desirable manufacturing properties
  • Analyzing cell clone stability profiles using the ChemStress Fingerprint and product-specific algorithms – shortening clone stability assessment timelines and reducing costs

12:00 pm

  • Traditional means to quantify growth and production rates for antibody-expressing CHO lines are often limited by cloning efficiencies (typically 5-50%) and the inability to handle large numbers of plates/flasks
  • Measurement of titer or productivity often requires more than 10,000 cells and current assay offers little to no insight into the behavior of sub-populations within each clone
  • A disposable nanofluidic chip housing over 1700 individual nanoscale bioreactors continuously perfused under culture conditions that lead to 60-80% cloning efficiency
  • Effectively characterizing cell growth, diameter and other phenotypic characteristics, presenting a new workflow where fully documented stable high producing monoclonal cell lines can be selected in under 1 month

12:30 pm

Networking Lunch

ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES 细胞系研发科技的革新

1:40 pm

  • Overview of the current regulatory position on monoclonality
  • A new, verified, analytical approach to the estimation of the probability of monoclonality that greatly improves the quality of monoclonality reporting in regulatory submissions.
  • Case studies covering the positive impact on workflow and laboratory efficiency
  • Application to CAR-T and targeted gene editing methods such as ZFNs, TALENS and CRISPR/Cas9

2:20 pm

  • Cell line development as a process
  • How to monitor/control the process
  • Early predictors of final outcomes

3:00 pm

Afternoon Networking & Refreshment Break

3:30 pm

  • Wave perfusion based seed train expansion vs. conventional fed batch based process, from 25L-2000L
  • Comparison of drug substances from different processes
  • Significant time and cost saving achieved with new process

QBD, PAT AND EARLY INTERVENTION STRATEGIES 和早期干预策略

4:00 pm

  • Changes in cell culture conditions affect more than just product yield & glycosylation steps
  • Working to reduce post-translational modifications, which could severely impact drug product quality
  • Happy cells for happy products: metabolite profiling as an indicator of cell line “happiness”

4:30 pm

  • N-Glycans play a critical role in the pharmacology of biotherapeutics
  • N-Glycan analysis has traditionally been a tedious and time-consuming process
  • Next-generation sample preparation and analytical methods shorten time to results from days to hours

5:00 pm

  • Development of a “design space” for integrating CQAs, risk assessment/management and control strategies
  • Identifying process parameters and interactions that adversely affect cell culture performance and product attributes early on, to prevent problems at late-stage cell culture
  • Ensuring consistency in delivery of a cell culture process for therapeutic mAbs

5:30 pm

  • Control of glycosylation patterns is essential for ensuring safety, efficacy and clearance of therapeutic product
  • More effective process optimization & purification for critical control
  • Improving analytical capabilities and glycoform analysis
  • Glycosylation issues and its relation to clinical trial PK

6:00 pm

Networking Cocktails

9:00 am

Chairperson’s Opening Remarks

Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS 细胞培养的新兴科技和应用

9:10 am

  • Currently there are no systematic analyses of small molecule function or platform technologies that permit cell culture engineers to rationally harness their potential to control manufacturing performance in a cell line and/or product specific manner
  • Development of a medium to high-throughput platform that enables rapid quantitative assessment of small molecules additives as a tool to create bespoke media environments designed to engineer cell factory function for optimal manufacturing performance

10:10 am

  • Examining critical factors for successful cell cultivation process transfer & scale-up
  • Development strategy for antibody medicine produced in mammalian cells
  • Optimizing cell culture factors and antibody production

10:40 am

Morning Networking & Refreshment Break

THERAPEUTIC MAB INNOVATION AND DISCOVERY 治疗性mAb创新和发展

11:10 am

  • Highlighting the potential to lead to a novel therapy principle for the treatment of diabesity, NASH
  • Dual activation of the GLP-1R and GCGR
  • A novel GLP-1/GCG chimeric peptide/Fc fusion protein – developed and exhibit potent body reduced effect, improvements in multiple metabolic parameters in DIO mouse

NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION SYSTEMS

11:40 am

Fireside Chat: Manufacturing Stable Expression Platforms by Gene Engineering Technology

Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

Wang Tong Ying, Chief Technical Officer, Hangzhou Jiuyuan Gene Engineering, China

12:10 pm

Networking Lunch

1:10 pm

  • Development of alternative expression systems especially for mAb variants without in vivo counterparts, new conjugated formats, or artificial molecules
  • Alternative expression systems offer biopharmaceutical manufacturers the chance to establish a stronger intellectual property position and improve their processes
  • Collaborating to advance novel expression technologies
  • Further advances and demonstration of utility

2:00 pm

  • Novel NGS-integrated approach to identify transcriptionally active site(s) and beyond
  • Constructing landing pad for site specific integration via CRISPR/Cas9-mediated genome editing
  • Design and execute a pooled CRISPR/Cas9 screen using a knowledge-based focused library

2:40 pm

  • Reviewing the latest developments and challenges in glycosylation analysis
  • Advantages of glyco-engineered cell lines for production of biobetter versions of therapeutic proteins

3:10 pm

  • Exploring transient gene expression models as an alternative to development of stable cell lines for early-stage development work
  • Enabling superior transfection efficiency and cell viability following transient transfection
  • Rapid generation of high-yield stable cell lines within lowered timeframes

3:40 pm

Afternoon Networking & Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

5:00 pm

Chairperson’s Summary and End of Main Conference Day Two

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird

 

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

VIP Programme

Become a VIP!
IBC Asia’s VIP Programme is an invitation only based network of the absolute top decision makers across specific industries. Our VIPs get an exclusively designed and tailored programme that enables them to network, indulge and enjoy, whilst experiencing a premium service for the duration of this event.

Dedicated to helping you find the most effective way of engaging with professionals and industry solution providers at our event, and scheduled alongside the main event line-up, it gives you an opportunity to glean benefits from the conference as well, and ensures that you get the most of your time on site with us.

Benefits of becoming a VIP:

  • 1-2-1 Meeting Service (Pre-scheduling meetings with your peers, speakers and other participants you may want to meet)
  • Closed Door Think Tank (An invitation-only forum headlined by an exclusive keynote address)
  • The VIP Lounge
  • Opening Ceremony (Access priority seats and be the first to engage with key speakers and other top decision makers)
  • Your Interview, Promoted Exclusively

A personalized VIP agenda will be sent to you via email upon receiving the confirmation of your registration.

To find out more, please contact:
Angeline Tan, VIP Relations Manager
Email: Angeline.Tan.SG1@ibcasia.com.sg
Phone: +65 6508 2874

Download VIP Programme brochure »

speakers

Dr. Ming Wang

President and Chief Executive Officer, Phanes Biopharmaceuticals, China

Xiao Zhi Hua

Chief Executive Officer, OPM Biosciences, China

Xu Wei

Vice President, Manufacturing, Innovent Biologics, China

Jerry Yang

SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China

Dr Jun Liu

Vice President, TOT Biopharma, China

Yanshan Huang

Chief Executive Officer, DOER Biologics, China

Andrew Huntley

Senior Managing Director, BDA Partners, UK

Sunny Zhou

Professor, Department of Chemistry and Chemical Biology Faculty Fellow, Barnett Institute of Chemical and Biological Analysis Northeastern University, Boston, Massachusetts

Jerry Clifford

Chief Operating Officer, Valitacell, Ireland

Keith Breinlinger

Chief Technology Officer, Berkeley Lights, USA

George Hutchinson

Head of Global Distribution, Solentim, UK

Eric Chang

Head of Cell Line Development, JHL Biotech, Taiwan

Dr. John Yan

Applications Scientist, ProZyme

Fai Poon Hung

President, Quacell Biotech, China

Julie Wei

Director, JUST Biotherapeutics, China

Sam Zhang

Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

Prof. David James

University of Sheffield

Ng Say Kong

Staff Scientist, Animal Cell Technology 2, Bioprocessing Technology Institute, A*STAR

Zhiwei Pan

Senior Director of Process Development, Livzon Mabpharm, China

Shaoqing Yang

Vice President, Zhejiang Doer Biologics Co.

Wang Tong Ying

Chief Technical Officer, Hangzhou Jiuyuan Gene Engineering, China

Dong Huifang

Director of Cell Line Development, WuXi Biologics, China

Sai Ling Liu

Product Development Expert, Surfer Biotech, China

Dr Jun Yuan

R&D Director, Quacell Biotechnology Co. Ltd, China

Zhou Hui

Chief Executive Officer, Glycogene Biotherapeutics, China

Yun Kang

Vice President of Manufacturing, Generon Beijing, China

Dr. Alvin Luk

Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

Zheru Zhang

President, I-Mab Biopharma, China

when & where

14 - 15 May 2019

contact

Still have a question?

Speaking Opportunities
Win Min
+65-6508 2873
Win.Min@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
June Tan
+65 6508 2465
June.Tan@ibcasia.com.sg

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more